Validation of a Dermatology-Specific Treatment Satisfaction Instrument

Validation of a Dermatology-Specific Treatment Satisfaction Instrument
warning The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05056168
Recruitment Status : **RECRUITING NOW**

First Posted : September 24, 2021

Last Update Posted : December 15, 2022

Sponsor:

Collaborators:

Information provided by (Responsible Party):

April Armstrong, University of Southern California

Go to 

Brief Summary:

The primary objective of this study is to validate a dermatology-specific questionnaire that assesses patient satisfaction with their treatments across various inflammatory dermatology diseases.

Psoriasis Other: Dermatology-Specific Treatment Satisfaction Instrument

Go to 

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of a Dermatology-Specific Treatment Satisfaction Instrument
Actual Study Start Date : November 13, 2021
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : May 2023
Resource links provided by the National Library of Medicine NIH NLM ABRV BLK 4

Go to 

Intervention Details:

  • Other: Dermatology-Specific Treatment Satisfaction Instrument

    Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients’ preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.

Go to 

Primary Outcome Measures :

  1. Validity and reliability of a dermatology-specific treatment satisfaction instrument in patients with psoriasis [ Time Frame: 8 months ]

    For this survey study, the investigators will gather descriptive statistics for each item in the questionnaire. The investigators will also measure the following psychometric properties: measurement error, reliability and construct validity, as measured by convergent and known-groups validity

Go to 

Information from the National Library of Medicine NIH NLM ABRV BLK 4

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample

Adult (≥ 18 years) dermatology patients with psoriasis from LAC+USC and Keck Medical Centers, the Brigham and Women’s Hospital, and the Mount Sinai Hospital.

Inclusion Criteria:

  • Adult (≥ 18 years)
  • Psoriasis patients undergoing some form of treatment

Go to 

Layout table for additonal information
Responsible Party: April Armstrong, Professor, University of Southern California
ClinicalTrials.gov Identifier: NCT05056168    
Other Study ID Numbers: HS-18-00891-AM004
First Posted: September 24, 2021    Key Record Dates
Last Update Posted: December 15, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 16, 2022Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Comments